Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S; ING114915 Study Team. Clotet B, et al. Among authors: pokrovskiy v. Lancet. 2014 Jun 28;383(9936):2222-31. doi: 10.1016/S0140-6736(14)60084-2. Epub 2014 Apr 1. Lancet. 2014. PMID: 24698485 Clinical Trial.
Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients.
Jemsek JG, Arathoon E, Arlotti M, Perez C, Sosa N, Pokrovskiy V, Thiry A, Soccodato M, Noor MA, Giordano M. Jemsek JG, et al. Among authors: pokrovskiy v. Clin Infect Dis. 2006 Jan 15;42(2):273-80. doi: 10.1086/498505. Epub 2005 Dec 5. Clin Infect Dis. 2006. PMID: 16355341 Clinical Trial.
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, Jemsek J, Rivero A, Rozenbaum W, Schrader S, Sension M, Vibhagool A, Thiry A, Giordano M. Squires K, et al. Among authors: pokrovskiy v. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1011-9. doi: 10.1097/00126334-200408150-00003. J Acquir Immune Defic Syndr. 2004. PMID: 15247553 Clinical Trial.
Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.
Wood R, Phanuphak P, Cahn P, Pokrovskiy V, Rozenbaum W, Pantaleo G, Sension M, Murphy R, Mancini M, Kelleher T, Giordano M. Wood R, et al. Among authors: pokrovskiy v. J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):684-92. doi: 10.1097/00126334-200406010-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15167287 Clinical Trial.
HIV epidemic in Russia and neighbouring countries.
Pokrovskiy V. Pokrovskiy V. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19502. doi: 10.7448/IAS.17.4.19502. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394011 Free PMC article.
25 results